PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 5:25 AM ET

Sponsor Check › Person

RL
No photo found yet (own website and image search run after this page is viewed)

Robert Langer

Named as an officer, director or promoter on SEC Form D filings · NY, MA, NC, CT, UT · Mar 20, 2009 → Jul 2, 2025

48deals (issuers)
$2.66Breported sold
1,192investors
175Form D filings
2009–2025years on file
Follow this personLook further ↓PDF

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:17 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Robert Langer is listed as a director and promoter on 175 SEC Form D filings by 48 issuers between Mar 2009 and Oct 2025. Largest by amount reported sold: Moderna Therapeutics, Inc. (Cambridge, MA — biotechnology — 2016; $451.4M reported sold to 72 investors), Moderna LLC (Cambridge, MA — pharmaceuticals — 2013–2015; $446.1M reported sold to 43 investors), T2 Biosystems, Inc. (Lexington, MA — other health care — 2010–2013; $400M reported sold to 16 investors), Humacyte, Inc. (Durham, NC — biotechnology — 2009–2018; $150M reported sold to 29 investors), Cartesian Therapeutics, Inc. (Gaithersburg, MD — biotechnology — 2010–2015; $130M reported sold to 26 investors) and 43 more (all listed below).

What this means That is a lot of deals — 48 separate companies raised money with this person listed as director and promoter, over about 16 years. Across those companies the filings report $2.66B sold in total.

Listed alongside Peter Barton Hutt (42 shared filings), Alan Crane (28 shared filings), Omid Farokhzad (21 shared filings), Carlo Giovanni Traverso (17 shared filings), Terrance McGuire (17 shared filings) and 353 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.

2 of the issuers belong to the sponsor group Moderna (2 issuers, $897.4M reported sold, 2013–2016).

What this means A sponsor group is one team that sets up a new company for each deal. Moderna has 2 companies on file and $897.4M reported sold in total — the group page shows the whole track record in one place.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — 12 bankruptcy cases matching the name listed in Key records below.

What this means 12 records came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared the newest 50 of 175 public filings for Robert Langer and found 13 differences, 2 worth asking the sponsor about: Amount sold went down between filings; 9 Form Ds were filed more than 15 days after the first sale; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Robert Langer has not run yet — it is joining a line of 15,517 names; searches run around the clock at the hosts' allowed rate. Searched so far: 28 names.

Community comments are quoted as written by their authors. Sources searched: BiggerPockets forums (via DuckDuckGo, Brave, Bing and BiggerPockets search) and Reddit (search feed + public archive).

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:17 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: AZ, CA, DE, TX, WA (crawled Oct 23, 2026)

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Robert Langer..

State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states are not covered.

3. Bankruptcies

12 cases: 12 closed (disposition not in docket feed)

Robert J Langer and Kelsie R Langer closed
United States Bankruptcy Court, W.D. Wisconsin · No. 1-20-10877 · Filed Mar 20, 2020 · Closed Jul 17, 2020
Role of Robert J Langer and Kelsie R Langer: Debtor · Outcome: Case closed 2020-07-17 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in WI (not a filing state)
Robert L Langer and Debra R Langer closed
United States Bankruptcy Court, D. Kansas · No. 18-11649 · Filed Aug 23, 2018 · Closed Mar 25, 2020
Role of Robert L Langer and Debra R Langer: Debtor · Outcome: Case closed 2020-03-25 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in KS (not a filing state)
Robert R Langer and Carol J Langer closed
United States Bankruptcy Court, W.D. Wisconsin · No. 1-18-11640 · Filed May 11, 2018 · Closed Aug 27, 2018
Role of Robert R Langer and Carol J Langer: Debtor · Outcome: Case closed 2018-08-27 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in WI (not a filing state)
Robert B. Langer and Virginia L. Langer closed
United States Bankruptcy Court, W.D. Wisconsin · No. 1-11-16684 · Filed Nov 1, 2011 · Closed Feb 13, 2012
Role of Robert B. Langer and Virginia L. Langer: Debtor · Outcome: Case closed 2012-02-13 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in WI (not a filing state)
Robert J. Langer and Selma A. Langer closed
United States Bankruptcy Court, W.D. Pennsylvania · No. 11-11585 · Filed Sep 29, 2011 · Closed Dec 4, 2014
Role of Robert J. Langer and Selma A. Langer: Debtor · Outcome: Case closed 2014-12-04 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in PA (not a filing state)
Robert L Langer closed
United States Bankruptcy Court, D. Kansas · No. 08-10783 · Filed Apr 9, 2008 · Closed Aug 6, 2008
Role of Robert L Langer: Debtor · Outcome: Case closed 2008-08-06 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in KS (not a filing state)
ROBERT R LANGER and ANN E LANGER closed
United States Bankruptcy Court, D. Minnesota · No. 02-41283 · Filed Apr 8, 2002 · Closed Jul 30, 2002
Role of ROBERT R LANGER and ANN E LANGER: Debtor · Outcome: Case closed 2002-07-30 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in MN (not a filing state)
Robert F. Langer and Patricia E. Langer closed
United States Bankruptcy Court, D. Maryland · No. 99-66157 · Filed Dec 15, 1999 · Closed Feb 2, 2001
Role of Robert F. Langer and Patricia E. Langer: Debtor · Outcome: Case closed 2001-02-02 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in the person's filing state (MD)
Robert W. Langer and Helen M. Langer closed
United States Bankruptcy Court, D. New Jersey · No. 98-30536 · Filed Jan 16, 1998 · Closed Jul 31, 1998
Role of Robert W. Langer and Helen M. Langer: Debtor · Outcome: Case closed 1998-07-31 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in the person's filing state (NJ)
Robert G. Langer closed
United States Bankruptcy Court, W.D. Pennsylvania · No. 95-22937 · Filed Aug 3, 1995 · Closed Nov 16, 1995
Role of Robert G. Langer: Debtor · Outcome: Case closed 1995-11-16 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in PA (not a filing state)
Robert W. Langer closed
United States Bankruptcy Court, D. Massachusetts · No. 95-11956 · Filed Mar 23, 1995 · Closed May 12, 1995
Role of Robert W. Langer: Debtor · Outcome: Case closed 1995-05-12 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in the person's filing state (MA)
Robert Langer closed
United States Bankruptcy Court, W.D. Wisconsin · No. 1-94-12785 · Filed Oct 17, 1994 · Closed Mar 9, 1995
Role of Robert Langer: Debtor · Outcome: Case closed 1995-03-09 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (a name found in 20 federal dockets); 4 people with this name in Form D filings; court in WI (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:17 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

13 differences found between the filings for Robert Langer — 2 worth asking about (compared the newest 50 of 175 filings on Oct 24, 2026; older filings not covered)

Worth asking · Mar 31, 2021 – Dec 23, 2022

Amount sold went down between filings — ZWI Therapeutics, Inc.

The Mar 31, 2021 filing says $5,000,000 sold; the Dec 23, 2022 Form D/A says $0 sold — $5,000,000 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Form D (earlier) · Mar 31, 2021 ↗Form D/A (later) · Dec 23, 2022 ↗ZWI Therapeutics, Inc. — PartnerFacts page ↗
Sources
Worth asking · Jan 11, 2019 – Oct 24, 2025

9 Form Ds were filed more than 15 days after the first sale

Form D filed 106 days after the first sale — Vivtex Corp · Form D filed 65 days after the first sale — Teal Bio, Inc. · Form D filed 52 days after the first sale — EpiBone, Inc. · Form D filed 28 days after the first sale — SYNTIS BIO, INC. · Form D filed 18 days after the first sale — Omnipulse Biosciences, Inc. · and 4 more

What this means Late notices are common and carry no penalty by themselves. A pattern of late paperwork is worth asking the sponsor about.

Form D · Aug 19, 2022 ↗Vivtex Corp — PartnerFacts page ↗Form D · Feb 5, 2021 ↗Teal Bio, Inc. — PartnerFacts page ↗
Sources
Note · Jun 12, 2020 – Feb 6, 2023

6 offerings changed their target amount between filings

Offering amount changed between filings — Teal Bio, Inc. · Offering amount changed between filings — SYNTIS BIO, INC. · Offering amount changed between filings — XENTER, INC. · Offering amount changed between filings — Landsdowne Labs, LLC · Offering amount changed between filings — Suono Bio, Inc. · and 1 more

What this means Targets change as deals grow or shrink. Ask whether later money has the same terms.

Form D (earlier) · Nov 23, 2021 ↗Form D/A (later) · Feb 6, 2023 ↗Teal Bio, Inc. — PartnerFacts page ↗Form D (earlier) · Aug 17, 2022 ↗
Sources
Note · Feb 23, 2018 – Jul 2, 2025

26 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — SYNTIS BIO, INC. (latest filing Jul 2, 2025) · No amendment in the last 12 months on an offering that may still be open — SYNTIS BIO, INC. (latest filing Jan 27, 2025) · No amendment in the last 12 months on an offering that may still be open — Omnipulse Biosciences, Inc. (latest filing Jan 2, 2024) · No amendment in the last 12 months on an offering that may still be open — Lyndra Therapeutics, Inc. (latest filing Dec 29, 2023) · No amendment in the last 12 months on an offering that may still be open — Teal Bio, Inc. (latest filing Dec 27, 2023) · and 21 more

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Form D · Jul 2, 2025 ↗SYNTIS BIO, INC. — PartnerFacts page ↗Form D · Jan 27, 2025 ↗Form D · Jan 2, 2024 ↗
Sources
Note · Mar 9, 2018 – Jun 26, 2018

Robert Langer is written 2 different ways on the filings

listed as "Robert Langer" on 45 filings (from Mar 9, 2018), and "Robert S. Langer" on 5 filings (from Jun 26, 2018).

What this means Same person, written differently — a middle name or suffix left off, or spelled another way. It is normal, but check that the full legal name matches your subscription documents.

Form D · Mar 9, 2018 ↗Form D · Jun 26, 2018 ↗Robert Langer — PartnerFacts page ↗
Sources
Note · Dec 13, 2019 – Oct 19, 2022

Industry group changed between filings — LUMINOPIA, INC.

"Other Health Care" (Dec 13, 2019); then "Biotechnology" (Oct 19, 2022 to Jun 29, 2023).

What this means The issuer described its business differently on different forms. Often it is just a different box ticked; sometimes the deal itself changed. Ask which business your money is in.

Form D · Dec 13, 2019 ↗Form D · Oct 19, 2022 ↗LUMINOPIA, INC. — PartnerFacts page ↗
Sources
Note · Mar 29, 2010 – Aug 27, 2026

Same name, different state: "Robert Langer" (PA) is a separate record

This page covers filings where the address state is NY or MA or NC or CT or UT. A separate record, "Robert Langer" with address state PA, is listed on 14 filings — most recently by Noveome Biotherapeutics, Inc. (Aug 27, 2026). Both records have filings in the same period (Mar 29, 2010 to Jul 2, 2025).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert Langer (PA) — PartnerFacts page ↗Form D · Aug 27, 2026 ↗Noveome Biotherapeutics, Inc. — PartnerFacts page ↗Robert Langer (NY,MA,NC,CT,UT) — this page ↗
Sources
Note · Apr 20, 2016 – Jun 19, 2019

Same name, different state: "Robert S Langer" (TX) is a separate record

This page covers filings where the address state is NY or MA or NC or CT or UT. A separate record, "Robert S Langer" with address state TX, is listed on 6 filings — most recently by StemBioSys Inc. (Dec 30, 2020). Both records have filings in the same period (Apr 20, 2016 to Jun 19, 2019).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert S Langer (TX) — PartnerFacts page ↗Form D · Dec 30, 2020 ↗StemBioSys Inc. — PartnerFacts page ↗Robert Langer (NY,MA,NC,CT,UT) — this page ↗
Sources
Note · Nov 16, 2010 – Mar 7, 2013

Same name, different state: "Robert Langer" (CA) is a separate record

This page covers filings where the address state is NY or MA or NC or CT or UT. A separate record, "Robert Langer" with address state CA, is listed on 2 filings — most recently by DX Biosciences, Inc. (Mar 7, 2013). Both records have filings in the same period (Nov 16, 2010 to Mar 7, 2013).

What this means Two records with one name were active at the same time. That can be one person listing different company addresses, or two different people. We keep them apart until a filing ties them together. Check both pages before you decide.

Robert Langer (CA) — PartnerFacts page ↗Form D · Mar 7, 2013 ↗DX Biosciences, Inc. — PartnerFacts page ↗Robert Langer (NY,MA,NC,CT,UT) — this page ↗
Sources
Note · Mar 31, 2021 – Oct 24, 2025

5 address changes between filings

Address moved from Brooklyn, NY to New York, NY — EpiBone, Inc. · Address moved from Milton, MA to Boston, MA — SYNTIS BIO, INC. · Address moved from Cambridge, MA to Foxborough, MA — Suono Bio, Inc. · Address moved from Salt Lake City, UT to Draper, UT — XENTER, INC. · Address moved from Cambridge, MA to Watertown, MA — ZWI Therapeutics, Inc.

What this means Businesses move. If you were told one city and the forms say another, ask which is current.

Form D · Dec 27, 2022 ↗Form D · Oct 24, 2025 ↗EpiBone, Inc. — PartnerFacts page ↗Form D/A · Jan 17, 2023 ↗
Sources
Note · Mar 9, 2018 – Oct 24, 2025

Robert Langer is listed with 5 different address states: NC, MA, CT, NY, UT

NC on 3 filings (Mar 9, 2018 to Aug 5, 2025); MA on 38 filings (Aug 22, 2018 to Jul 2, 2025); CT on 3 filings (Oct 23, 2020 to Oct 8, 2021); NY on 3 filings (Feb 12, 2021 to Oct 24, 2025); UT on 3 filings (Jul 14, 2021 to Jan 6, 2023).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Form D · Mar 9, 2018 ↗Form D · Aug 22, 2018 ↗Form D · Oct 23, 2020 ↗Form D · Feb 12, 2021 ↗
Sources
Note · Sep 22, 2021 – Oct 8, 2021

Minimum investment changed between filings — Landsdowne Labs, LLC

The Sep 22, 2021 filing lists a minimum of $12,500; the Oct 8, 2021 Form D/A lists $10,000.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D/A (earlier) · Sep 22, 2021 ↗Form D/A (later) · Oct 8, 2021 ↗Landsdowne Labs, LLC — PartnerFacts page ↗
Sources
Note · Oct 23, 2020 – Sep 22, 2021

Minimum investment changed between filings — Landsdowne Labs, LLC

The Oct 23, 2020 filing lists a minimum of $25,000; the Sep 22, 2021 Form D/A lists $12,500.

What this means A different minimum usually means the offering terms changed. Check which terms apply to you.

Form D (earlier) · Oct 23, 2020 ↗Form D/A (later) · Sep 22, 2021 ↗Landsdowne Labs, LLC — PartnerFacts page ↗
Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. We compared the newest 50 of 175 filings (work cap); older filings are not covered here. As of Oct 24, 2026.

5. Money to insiders

6 of 139 offerings report sales commissions totalling $2,239,588; 3 report finder's fees totalling $1,857,864; 9 report proceeds to related persons totalling $8,579,750. (includes amounts the issuer reported as estimates)

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Oct 24, 2025 D
EpiBone, Inc.
File 021-562009
$0$0$0None listed on this filingEDGAR ↗
Aug 5, 2025 D
VitaKey Inc.
File 021-553682
$0$0$0None listed on this filingEDGAR ↗
Jul 2, 2025 D
SYNTIS BIO, INC.
File 021-550616
$0$0$0None listed on this filingEDGAR ↗
Jan 27, 2025 D
SYNTIS BIO, INC.
File 021-536247
$0$0$0None listed on this filingEDGAR ↗
Jan 2, 2024 D
Omnipulse Biosciences, Inc.
File 021-501260
$0$0$1,450,000 (est.)None listed on this filingEDGAR ↗
Dec 29, 2023 D
Lyndra Therapeutics, Inc.
File 021-501189
$0$0$0None listed on this filingEDGAR ↗
Dec 27, 2023 D
Teal Bio, Inc.
File 021-500840
$0$0$0None listed on this filingEDGAR ↗
Aug 28, 2023 D
Suono Bio, Inc.
File 021-490779
$0$0$0None listed on this filingEDGAR ↗
Aug 4, 2023 D
Bilayer Therapeutics, Inc.
File 021-488766
$0$0$0None listed on this filingEDGAR ↗
Jun 29, 2023 D
LUMINOPIA, INC.
File 021-485522
$0$0$0None listed on this filingEDGAR ↗
Jun 7, 2023 D
Lyndra Therapeutics, Inc.
File 021-483559
$0$0$0None listed on this filingEDGAR ↗
Feb 6, 2023 D/A
Teal Bio, Inc.
File 021-422314
$0$0$0None listed on this filingEDGAR ↗
Jan 17, 2023 D/A
SYNTIS BIO, INC.
File 021-456192
$0$0$0None listed on this filingEDGAR ↗
Jan 6, 2023 D/A
XENTER, INC.
File 021-406110
$0$0$1,100,000 (est.)None listed on this filingEDGAR ↗
Jan 6, 2023 D
XENTER, INC.
File 021-469856
$0$0$1,200,000 (est.)None listed on this filingEDGAR ↗
Dec 27, 2022 D
EpiBone, Inc.
File 021-468742
$0$0$0None listed on this filingEDGAR ↗
Dec 23, 2022 D/A
ZWI Therapeutics, Inc.
File 021-394203
$0$0$0None listed on this filingEDGAR ↗
Oct 19, 2022 D
LUMINOPIA, INC.
File 021-462268
$0$0$0None listed on this filingEDGAR ↗
Aug 19, 2022 D
Vivtex Corp
File 021-456319
$0$0$0None listed on this filingEDGAR ↗
Apr 6, 2022 D
Abpro Corp
File 021-440631
$0$0$0None listed on this filingEDGAR ↗
Dec 17, 2021 D
SunBird Bio, Inc.
File 021-425703
$0$0$0None listed on this filingEDGAR ↗
Oct 8, 2021 D/A
Landsdowne Labs, LLC
File 021-378719
$12,700$0$200,000 (est.)Hubble Investments LLC BrokerCheck CRD 289415 ↗
via Hubble Investments LLC (CRD 289415 ↗)
EDGAR ↗
Jul 7, 2021 D/A
Suono Bio, Inc.
File 021-393479
$0$0$0None listed on this filingEDGAR ↗
Jul 1, 2021 D/A
SunBird Bio, Inc.
File 021-368862
$0$0$0None listed on this filingEDGAR ↗
Jun 23, 2021 D
Lyndra Therapeutics, Inc.
File 021-403985
$0$0$0None listed on this filingEDGAR ↗
Jun 14, 2021 D
LikeMinds, Inc./DE
File 021-402731
$0$0$0None listed on this filingEDGAR ↗
Apr 29, 2021 D
Bilayer Therapeutics, Inc.
File 021-397597
$0$0$0None listed on this filingEDGAR ↗
Apr 14, 2021 D
Kendall Capital Partners I, L.P.
File 021-395860
$0$0$0
General Partner will be paid a Management Fee as described in Partnership Agreement. Amount is indeterminate at this time.
None listed on this filingEDGAR ↗
Feb 12, 2021 D
EpiBone, Inc.
File 021-389274
$0$0$0None listed on this filingEDGAR ↗
Feb 5, 2021 D
Teal Bio, Inc.
File 021-388615
$0$0$0None listed on this filingEDGAR ↗
Jul 27, 2020 D
Frequency Therapeutics, Inc.
File 021-371826
$2,045,098$0$0Cowen and Company, LLC BrokerCheck CRD 7616 ↗EDGAR ↗
Jan 28, 2020 D
Abpro Corp
File 021-359062
$0$0$0None listed on this filingEDGAR ↗
Jan 27, 2020 D
Lyra Therapeutics, Inc.
File 021-359027
$0$0$0None listed on this filingEDGAR ↗
Dec 26, 2019 D
Tarveda Therapeutics, Inc.
File 021-356423
$0$0$0None listed on this filingEDGAR ↗
Dec 13, 2019 D
LUMINOPIA, INC.
File 021-355537
$0$0$0None listed on this filingEDGAR ↗
Jul 23, 2019 D
Frequency Therapeutics, Inc.
File 021-344894
$0$0$0None listed on this filingEDGAR ↗
Jun 7, 2019 D
Arsenal Medical, Inc.
File 021-341425
$0$0$0None listed on this filingEDGAR ↗
Jan 28, 2019 D
Lyndra Therapeutics, Inc.
File 021-331551
$0$0$0None listed on this filingEDGAR ↗
Sep 20, 2018 D
LikeMinds, Inc./DE
File 021-321800
$0$0$0None listed on this filingEDGAR ↗
Aug 22, 2018 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-319773
$0$0$0None listed on this filingEDGAR ↗
Jun 26, 2018 D
Humacyte, Inc.
File 021-315399
$0$0$0None listed on this filingEDGAR ↗
Mar 9, 2018 D
Humacyte, Inc.
File 021-307330
$0$0$0None listed on this filingEDGAR ↗
Mar 1, 2018 D
Rubius Therapeutics, Inc.
File 021-306744
$0$0$0None listed on this filingEDGAR ↗
Feb 21, 2018 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-306068
$0$0$0None listed on this filingEDGAR ↗
Feb 6, 2018 D
Landsdowne Labs, LLC
File 021-304899
$0$0$250,000 (est.)None listed on this filingEDGAR ↗
Jan 4, 2018 D
Seer Biosciences, Inc.
File 021-302425
$0$0$425,000 (est.)
Some of the directors and officers of the Issuer listed in Item 3 will receive compensation in connection with their service or employment with the Issuer.
None listed on this filingEDGAR ↗
Dec 12, 2017 D
Combined Therapeutics, Inc.
File 021-300496
$0$0$0None listed on this filingEDGAR ↗
Sep 20, 2017 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-295080
$17,500$0$0OUISA CAPITAL LLC BrokerCheck CRD 102840 ↗EDGAR ↗
Sep 19, 2017 D/A
MICELL TECHNOLOGIES INC
File 021-274784
$28,040$0$0Invemed Associates LLC BrokerCheck CRD 6728 ↗EDGAR ↗
Jun 23, 2017 D
Suono Bio, Inc.
File 021-289354
$0$0$0None listed on this filingEDGAR ↗
Jun 22, 2017 D
Rubius Therapeutics, Inc.
File 021-289273
$0$0$0None listed on this filingEDGAR ↗
Apr 19, 2017 D/A
Lyndra Therapeutics, Inc.
File 021-266863
$0$0$0None listed on this filingEDGAR ↗
Apr 14, 2017 D
Frequency Therapeutics, Inc.
File 021-284867
$0$0$0None listed on this filingEDGAR ↗
Mar 30, 2017 D
Verseau Therapeutics, Inc.
File 021-283695
$0$0$0 (est.)
Proceeds are for working capital. The number above excludes use of proceeds for normal salary and bonus to executive officers.
None listed on this filingEDGAR ↗
Feb 9, 2017 D/A
Tarveda Therapeutics, Inc.
File 021-256322
$0$720,000 (est.)$2,500,000 (est.)MTS Securities, LLC BrokerCheck CRD 104059 ↗EDGAR ↗
Feb 9, 2017 D
Tarveda Therapeutics, Inc.
File 021-280364
$0$0$0None listed on this filingEDGAR ↗
Nov 28, 2016 D
Lyra Therapeutics, Inc.
File 021-275206
$0$0$0None listed on this filingEDGAR ↗
Nov 16, 2016 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-274591
$0$0$0None listed on this filingEDGAR ↗
Sep 2, 2016 D/A
XTuit Pharmaceuticals, Inc.
File 021-229519
$0$0$0None listed on this filingEDGAR ↗
Aug 24, 2016 D
Moderna Therapeutics, Inc.
File 021-269500
$0$0$0None listed on this filingEDGAR ↗
Apr 13, 2016 D
KALA BIO, Inc.
File 021-261236
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2015 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-253617
$0$0$0None listed on this filingEDGAR ↗
Sep 10, 2015 D
Cartesian Therapeutics, Inc.
File 021-247362
$0$0$0None listed on this filingEDGAR ↗
Aug 19, 2015 D
KALA BIO, Inc.
File 021-246095
$0$0$0None listed on this filingEDGAR ↗
Aug 6, 2015 D/A
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-222564
$0$0$0None listed on this filingEDGAR ↗
Jun 24, 2015 D
Microchips Biotech, Inc.
File 021-242364
$0$0$0None listed on this filingEDGAR ↗
Apr 23, 2015 D
Cartesian Therapeutics, Inc.
File 021-238498
$0$0$0None listed on this filingEDGAR ↗
Jan 20, 2015 D/A
Humacyte, Inc.
File 021-109988
$0$0$0None listed on this filingEDGAR ↗
Jan 5, 2015 D
Moderna LLC
File 021-231445
$0$0$0None listed on this filingEDGAR ↗
Aug 28, 2014 D
Cartesian Therapeutics, Inc.
File 021-223752
$0$0$0None listed on this filingEDGAR ↗
Jul 15, 2014 D
Cartesian Therapeutics, Inc.
File 021-221143
$0$0$0None listed on this filingEDGAR ↗
Jun 18, 2014 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-219417
$0$0$0None listed on this filingEDGAR ↗
Apr 24, 2014 D
KALA BIO, Inc.
File 021-216153
$0$0$0None listed on this filingEDGAR ↗
Apr 10, 2014 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-215310
$0$0$0None listed on this filingEDGAR ↗
Apr 9, 2014 D
Cartesian Therapeutics, Inc.
File 021-215195
$0$0$0None listed on this filingEDGAR ↗
Apr 3, 2014 D
SQZ Biotechnologies Co
File 021-214833
$0$0$0None listed on this filingEDGAR ↗
Mar 12, 2014 D
Tarveda Therapeutics, Inc.
File 021-213366
$0$0$0None listed on this filingEDGAR ↗
Jan 31, 2014 D
XTuit Pharmaceuticals, Inc.
File 021-211055
$0$0$0None listed on this filingEDGAR ↗
Jan 23, 2014 D/A
Moderna LLC
File 021-206659
$0$0$0None listed on this filingEDGAR ↗
Dec 24, 2013 D/A
Tarveda Therapeutics, Inc.
File 021-188774
$0$0$0None listed on this filingEDGAR ↗
Nov 21, 2013 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-206725
$0$0$0None listed on this filingEDGAR ↗
Oct 25, 2013 D
EGEN, Inc.
File 021-205320
$0$0$0None listed on this filingEDGAR ↗
Sep 5, 2013 D
Arsenal Medical, Inc.
File 021-202364
$0$0$0None listed on this filingEDGAR ↗
Apr 12, 2013 D
Lyra Therapeutics, Inc.
File 021-194960
$0$0$0None listed on this filingEDGAR ↗
Apr 4, 2013 D/A
TARIS BIOMEDICAL INC
File 021-158321
$0$0$0
This amendment is being filed to withdraw the Form D amendment filed on April 2, 2013 which was inadvertently submitted.
None listed on this filingEDGAR ↗
Apr 1, 2013 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-194292
$0$0$0None listed on this filingEDGAR ↗
Mar 28, 2013 D
T2 Biosystems, Inc.
File 021-194118
$0$0$0None listed on this filingEDGAR ↗
Mar 18, 2013 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-193494
$0$0$0None listed on this filingEDGAR ↗
Mar 11, 2013 D/A
Biorez, Inc.
File 021-166577
$0$0$654,750 (est.)None listed on this filingEDGAR ↗
Feb 28, 2013 D
KALA BIO, Inc.
File 021-192576
$0$0$0None listed on this filingEDGAR ↗
Feb 25, 2013 D
LIVING PROOF INC
File 021-192312
$0$1,122,864$0Leerink Swann LLC BrokerCheck CRD 39011 ↗
via Daniel Dubin (CRD 3231063 ↗)
EDGAR ↗
Feb 8, 2013 D
BIND Biosciences, Inc
File 021-191591
$0$0$0None listed on this filingEDGAR ↗
Oct 30, 2012 D
Lyra Therapeutics, Inc.
File 021-186251
$0$0$0None listed on this filingEDGAR ↗
Oct 4, 2012 D
Arsenal Medical, Inc.
File 021-185002
$0$0$0None listed on this filingEDGAR ↗
Oct 1, 2012 D
Combinent BioMedical Systems, Inc.
File 021-184827
$0$0$0None listed on this filingEDGAR ↗
Sep 21, 2012 D
EGEN, Inc.
File 021-184432
$0$0$0None listed on this filingEDGAR ↗
Sep 19, 2012 D
EGEN, Inc.
File 021-184324
$0$0$0None listed on this filingEDGAR ↗
Jun 19, 2012 D/A
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-159505
$0$0$0None listed on this filingEDGAR ↗
Jun 1, 2012 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-179118
$0$0$0None listed on this filingEDGAR ↗
Apr 10, 2012 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-176410
$0$0$0None listed on this filingEDGAR ↗
Mar 14, 2012 D
KALA BIO, Inc.
File 021-174916
$0$0$0None listed on this filingEDGAR ↗
Jan 4, 2012 D
Combinent BioMedical Systems, Inc.
File 021-171122
$0$0$0None listed on this filingEDGAR ↗
Nov 22, 2011 D
BIND Biosciences, Inc
File 021-169119
$0$0$0None listed on this filingEDGAR ↗
Nov 17, 2011 D
Cartesian Therapeutics, Inc.
File 021-168905
$0$0$0
None other than salaries and bonuses in the ordinary course of business.
None listed on this filingEDGAR ↗
Nov 17, 2011 D
Cartesian Therapeutics, Inc.
File 021-168906
$0$0$0
None other than salaries and bonuses in the ordinary course of business.
None listed on this filingEDGAR ↗
Nov 8, 2011 D
Lyra Therapeutics, Inc.
File 021-168351
$0$0$0None listed on this filingEDGAR ↗
Oct 13, 2011 D
BIND Biosciences, Inc
File 021-167172
$0$0$0None listed on this filingEDGAR ↗
Sep 16, 2011 D
Arsenal Medical, Inc.
File 021-166006
$0$0$0None listed on this filingEDGAR ↗
Sep 8, 2011 D
Lyra Therapeutics, Inc.
File 021-165491
$0$0$0None listed on this filingEDGAR ↗
Sep 8, 2011 D
Arsenal Medical, Inc.
File 021-165493
$0$0$0None listed on this filingEDGAR ↗
Sep 2, 2011 D
Tarveda Therapeutics, Inc.
File 021-165360
$0$0$0None listed on this filingEDGAR ↗
Aug 10, 2011 D
T2 Biosystems, Inc.
File 021-164197
$0$0$0None listed on this filingEDGAR ↗
Dec 29, 2010 D
Combinent BioMedical Systems, Inc.
File 021-152699
$0$0$0None listed on this filingEDGAR ↗
Dec 22, 2010 D
SEMPRUS BIOSCIENCES CORP
File 021-152404
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2010 D
KALA BIO, Inc.
File 021-150327
$0$0$0None listed on this filingEDGAR ↗
Oct 14, 2010 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-149086
$0$0$0None listed on this filingEDGAR ↗
Oct 13, 2010 D
Dare Bioscience, Inc.
File 021-148928
$0$0$0None listed on this filingEDGAR ↗
Sep 29, 2010 D
Combinent BioMedical Systems, Inc.
File 021-148290
$0$0$0None listed on this filingEDGAR ↗
Aug 12, 2010 D
Lyra Therapeutics, Inc.
File 021-146298
$0$0$0None listed on this filingEDGAR ↗
Jul 7, 2010 D/A
Biorez, Inc.
File 021-116685
$0$0$800,000 (est.)None listed on this filingEDGAR ↗
Jun 29, 2010 D
BIND Biosciences, Inc
File 021-144139
$0$0$0
Not including salaries and bonuses paid to executive officers in the ordinary course of business.
None listed on this filingEDGAR ↗
Jun 21, 2010 D
PREDICTIVE BIOSCIENCES, INC
File 021-143788
$0$0$0
Not including salaries and bonuses paid to executive officers in the ordinary course of business.
None listed on this filingEDGAR ↗
Jun 9, 2010 D
Dare Bioscience, Inc.
File 021-143174
$0$0$0None listed on this filingEDGAR ↗
Jun 4, 2010 D
SEVENTH SENSE BIOSYSTEMS, INC.
File 021-142974
$0$0$0None listed on this filingEDGAR ↗
May 28, 2010 D
T2 Biosystems, Inc.
File 021-142704
$0$0$0None listed on this filingEDGAR ↗
May 18, 2010 D
Lyra Therapeutics, Inc.
File 021-142233
$0$0$0None listed on this filingEDGAR ↗
Apr 6, 2010 D
Cartesian Therapeutics, Inc.
File 021-125893
$0$0$0
None other than salaries and bonuses in the ordinary course of business.
None listed on this filingEDGAR ↗
Mar 19, 2010 D
Lyra Therapeutics, Inc.
File 021-77033
$0$0$0None listed on this filingEDGAR ↗
Jan 19, 2010 D
PREDICTIVE BIOSCIENCES, INC
File 021-124007
$0$0$0
Not including salaries and bonuses paid to executive officers in the ordinary course of business
None listed on this filingEDGAR ↗
Dec 23, 2009 D
KALA BIO, Inc.
File 021-137165
$0$0$0None listed on this filingEDGAR ↗
Dec 16, 2009 D
Combinent BioMedical Systems, Inc.
File 021-106562
$0$0$0None listed on this filingEDGAR ↗
Dec 16, 2009 D
TARIS BIOMEDICAL INC
File 021-122485
$0$0$0None listed on this filingEDGAR ↗
Dec 7, 2009 D
Echo Therapeutics, Inc.
File 021-59012
$44,375$0$0BOENNING & SCATTERGOOD, INC. BrokerCheck CRD 100 ↗EDGAR ↗
Dec 3, 2009 D
MICELL TECHNOLOGIES INC
File 021-45412
$0$0$0None listed on this filingEDGAR ↗
Nov 10, 2009 D
ALSERES PHARMACEUTICALS INC /DE
File 021-09478-4B
$0$0$0None listed on this filingEDGAR ↗
Sep 15, 2009 D
Pervasis Therapeutics Inc
File 021-71452
$91,875 (est.)$15,000$0Musket Research Associates, Inc. BrokerCheck CRD 30599 ↗
via David B. Musket (CRD 1321808 ↗)
EDGAR ↗
Jul 27, 2009 D
Dare Bioscience, Inc.
File 021-104032
$0$0$0None listed on this filingEDGAR ↗
Jun 18, 2009 D
LIVING PROOF INC
File 021-108750
$0$0$0None listed on this filingEDGAR ↗
Mar 20, 2009 D
Microchips Biotech, Inc.
File 021-43521
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 48

Every issuer that named Robert Langer on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

E
Other

EpiBone, Inc.

New York, NY · Feb 12, 2021 → Oct 24, 2025 · 3 filings
  • Oct 24, 2025 · D · $4,287,429 sold of $4,300,506 · 131 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 27, 2022 · D · $18,453,016 sold of $36,762,017 · 51 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 12, 2021 · D · $750,000 sold of $5,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $24.3M from 140 investors (100% of the $4.3M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

V
Other Technology

VitaKey Inc.

Durham, NC · Aug 5, 2025
  • Aug 5, 2025 · D · $0 sold of $43,542,640 · 0 investors · min. No minimum reported · role: Director EDGAR ↗

No sales reported yet as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

SYNTIS BIO, INC.

Boston, MA · Aug 17, 2022 → Jul 2, 2025 · 4 filings
  • Jul 2, 2025 · D · $24,983,429 sold of $26,483,445 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 27, 2025 · D · $6,316,555 sold of $9,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 17, 2023 · D/A · $15,372,179 sold of $15,372,179 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 17, 2022 · D · $11,189,985 sold of $11,189,985 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25M from 15 investors (94% of the $26.5M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

OB
Biotechnology

Omnipulse Biosciences, Inc.

Cambridge, MA · Jan 2, 2024
  • Jan 2, 2024 · D · $6,999,999 sold of $12,500,000 · 2 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗

Raised $7M from 2 investors (56% of the $12.5M target) as of the latest filing. Robert is listed as director, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Biotechnology

Lyndra Therapeutics, Inc.

Watertown, MA · Jul 13, 2016 → Dec 29, 2023 · 8 filings
  • Dec 29, 2023 · D · $122,749,667 sold of $206,055,340 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 7, 2023 · D · $20,350,715 sold of $179,262,848 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 23, 2021 · D · $60,470,112 sold of $65,000,000 · 22 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 28, 2019 · D · $55,243,392 sold of $60,903,006 · 23 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 19, 2017 · D/A · $23,082,575 sold of $23,082,575 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 7, 2017 · D/A · $20,082,575 sold of $20,082,575 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 10, 2017 · D/A · $17,082,576 sold of $17,082,576 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 13, 2016 · D · $5,932,584 sold of $5,932,584 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $122.7M from 23 investors (60% of the $206.1M target) as of the latest filing. Robert is listed as director on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TB
Other Health Care

Teal Bio, Inc.

Somerville, MA · Feb 5, 2021 → Dec 27, 2023 · 4 filings
  • Dec 27, 2023 · D · $218,634 sold of $950,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 6, 2023 · D/A · $3,000,000 sold of $3,000,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 23, 2021 · D · $2,500,000 sold of $2,500,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 5, 2021 · D · $575,000 sold of $575,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3M from 15 investors (100% of the $950K target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

Suono Bio, Inc.

Foxborough, MA · Jun 23, 2017 → Aug 28, 2023 · 4 filings
  • Aug 28, 2023 · D · $500,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 7, 2021 · D/A · $12,176,840 sold of $15,237,250 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 25, 2021 · D · $6,676,839 sold of $13,737,249 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 23, 2017 · D · $1,300,000 sold of $2,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $12.2M from 11 investors (100% of the $3M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

BT
Biotechnology

Bilayer Therapeutics, Inc.

Cambridge, MA · Apr 29, 2021 → Aug 4, 2023 · 2 filings
  • Aug 4, 2023 · D · $300,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 29, 2021 · D · $2,000,000 sold of $3,600,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $2M from 2 investors (100% of the $1M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

L
Biotechnology

LUMINOPIA, INC.

Cambridge, MA · Dec 13, 2019 → Jun 29, 2023 · 3 filings
  • Jun 29, 2023 · D · $15,811,759 sold of $16,811,759 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 19, 2022 · D · $4,074,997 sold of $5,134,997 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 13, 2019 · D · $11,110,726 sold of $13,611,012 · 29 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $15.8M from 29 investors (94% of the $16.8M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

X
Biotechnology

XENTER, INC.

Draper, UT · Jul 14, 2021 → Jan 6, 2023 · 3 filings
  • Jan 6, 2023 · D/A · $19,595,500 sold of $20,000,000 · 79 investors · min. $100,000 · role: Director EDGAR ↗
  • Jan 6, 2023 · D · $1,131,800 sold of $40,000,000 · 12 investors · min. $100,000 · role: Director EDGAR ↗
  • Jul 14, 2021 · D · $1,000,000 sold of $10,000,000 · 1 investors · min. $100,000 · role: Director EDGAR ↗

Raised $19.6M from 79 investors (98% of the $20M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

ZT
Biotechnology

ZWI Therapeutics, Inc.

Watertown, MA · Mar 31, 2021 → Dec 23, 2022 · 2 filings
  • Dec 23, 2022 · D/A · $0 sold of $10,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 31, 2021 · D · $5,000,000 sold of $10,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5M from 2 investors (50% of the $10M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VC
Biotechnology

Vivtex Corp

Cambridge, MA · Aug 19, 2022
  • Aug 19, 2022 · D · $1,800,000 sold of $1,800,000 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $1.8M from 14 investors (100% of the $1.8M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AC
Biotechnology

Abpro Corp

Woburn, MA · Jan 28, 2020 → Apr 6, 2022 · 2 filings
  • Apr 6, 2022 · D · $1,999,998 sold of $80,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 28, 2020 · D · $17,999,992 sold of $40,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18M from 7 investors (22% of the $80M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

SunBird Bio, Inc.

Cambridge, MA · Jun 12, 2020 → Dec 17, 2021 · 3 filings
  • Dec 17, 2021 · D · $17,999,987 sold of $17,999,987 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 1, 2021 · D/A · $46,699,979 sold of $46,699,979 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 12, 2020 · D · $26,106,974 sold of $45,000,000 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $46.7M from 19 investors (100% of the $18M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LL
Other Health Care

Landsdowne Labs, LLC

Fairfield, CT · Feb 6, 2018 → Oct 8, 2021 · 4 filings
  • Oct 8, 2021 · D/A · $2,159,376 sold of $2,500,000 · 42 investors · min. $10,000 · role: Director EDGAR ↗
  • Sep 22, 2021 · D/A · $1,667,376 sold of $2,500,000 · 36 investors · min. $12,500 · role: Director EDGAR ↗
  • Oct 23, 2020 · D · $463,950 sold of $2,000,000 · 8 investors · min. $25,000 · role: Director EDGAR ↗
  • Feb 6, 2018 · D · $1,644,999 sold of $2,600,000 · 10 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗

Raised $2.16M from 42 investors (86% of the $2.5M target) as of the latest filing. Robert is listed as director, promoter on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LD
Biotechnology

LikeMinds, Inc./DE

Boston, MA · Sep 20, 2018 → Jun 14, 2021 · 2 filings
  • Jun 14, 2021 · D · $1,146,042 sold of $1,146,042 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 20, 2018 · D · $5,222,671 sold of $5,222,671 · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $5.22M from 12 investors (100% of the $1.15M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

KC
Pooled Investment Fund

Kendall Capital Partners I, L.P.

Boston, MA · Apr 14, 2021
  • Apr 14, 2021 · D · $8,650,000 sold of Indefinite · 12 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $8.65M from 12 investors as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pooled Investment Fund / 506(b) (83,801 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

FT
Biotechnology

Frequency Therapeutics, Inc.

Woburn, MA · Apr 14, 2017 → Jul 27, 2020 · 3 filings
  • Jul 27, 2020 · D · $42,301,944 sold of $42,301,944 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 23, 2019 · D · $61,999,366 sold of $61,999,366 · 80 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 14, 2017 · D · $32,000,000 sold of $32,000,000 · 90 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $62M from 90 investors (100% of the $42.3M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

LT
Other

Lyra Therapeutics, Inc.

Watertown, MA · Apr 14, 2009 → Jan 27, 2020 · 11 filings
  • Jan 27, 2020 · D · $28,049,999 sold of $28,049,999 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 28, 2016 · D · $5,999,999 sold of $5,999,999 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 12, 2013 · D · $17,956,999 sold of $21,213,551 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 30, 2012 · D · $5,078,139 sold of $6,000,000 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 8, 2011 · D · $3,000,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 8, 2011 · D · $12,000,000 sold of $18,000,002 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 12, 2010 · D · $3,000,000 sold of $3,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 18, 2010 · D · $10,051,308 sold of $10,051,308 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 19, 2010 · D · $1,000,000 sold of $1,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 20, 2010 · D · $2,050,000 sold of $2,050,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 14, 2009 · D · $8,187,500 sold of $12,187,500 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $100.5M from 34 investors (100% of the $28M target) as of the latest filing. Robert is listed as director on 11 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other / 506(b) (18,678 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TT
Biotechnology

Tarveda Therapeutics, Inc.

Watertown, MA · Sep 2, 2011 → Dec 26, 2019 · 8 filings
  • Dec 26, 2019 · D · $13,634,188 sold of $13,634,188 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 9, 2017 · D · $30,000,001 sold of $30,000,001 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 9, 2017 · D/A · $38,000,000 sold of $38,000,000 · 8 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Jan 29, 2016 · D · $25,519,178 sold of $38,000,000 · 8 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗
  • Mar 12, 2014 · D · $999,999 sold of $999,999 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 24, 2013 · D/A · $21,001,164 sold of $21,001,168 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 20, 2012 · D · $16,001,168 sold of $21,001,168 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 2, 2011 · D · $2,800,000 sold of $2,800,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $38M from 13 investors (100% of the $13.6M target) as of the latest filing. Robert is listed as director, promoter on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

AM
Biotechnology

Arsenal Medical, Inc.

Watertown, MA · Sep 8, 2011 → Jun 7, 2019 · 5 filings
  • Jun 7, 2019 · D · $6,017,967 sold of $6,017,967 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 5, 2013 · D · $4,000,000 sold of $4,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 4, 2012 · D · $3,000,000 sold of $3,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 16, 2011 · D · $3,000,000 sold of $3,000,000 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 8, 2011 · D · $1 sold of $1 · 38 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6.02M from 38 investors (100% of the $6.02M target) as of the latest filing. Robert is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SS
Biotechnology

SEVENTH SENSE BIOSYSTEMS, INC.

Medford, MA · Jun 4, 2010 → Aug 22, 2018 · 18 filings
  • Aug 22, 2018 · D · $18,458,837 sold of $20,483,208 · 18 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 21, 2018 · D · $3,459,381 sold of $5,500,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 20, 2017 · D · $2,500,000 sold of $10,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 16, 2016 · D · $5,500,000 sold of $12,750,000 · 7 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 22, 2015 · D · $2,060,000 sold of $2,060,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 6, 2015 · D/A · $14,287,084 sold of $16,287,084 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 8, 2014 · D · $10,467,084 sold of $16,467,084 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 18, 2014 · D · $450,000 sold of $450,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 10, 2014 · D · $930,000 sold of $930,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 21, 2013 · D · $360,000 sold of Indefinite · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2013 · D · $157,500 sold of $157,500 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 18, 2013 · D · $1,800,000 sold of $1,800,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 19, 2012 · D/A · $12,182,963 sold of $12,182,963 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 1, 2012 · D · $200,000 sold of $200,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 10, 2012 · D · $750,000 sold of $750,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 10, 2011 · D · $6,682,964 sold of $12,182,962 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 14, 2010 · D · $2,100,000 sold of $2,100,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 4, 2010 · D · $1,500,000 sold of $1,500,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.5M from 18 investors (90% of the $20.5M target) as of the latest filing. Robert is listed as director on 18 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

H
Biotechnology

Humacyte, Inc.

Durham, NC · Nov 23, 2009 → Jun 26, 2018 · 7 filings
  • Jun 26, 2018 · D · $150,000,000 sold of $150,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 9, 2018 · D · $74,999,980 sold of $75,000,000 · 29 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 20, 2015 · D/A · $49,762,373 sold of $73,762,373 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 21, 2014 · D/A · $37,262,373 sold of $49,100,000 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 9, 2012 · D/A · $22,000,000 sold of $27,000,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 2, 2010 · D/A · $12,000,000 sold of $12,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 23, 2009 · D/A · $7,000,000 sold of $7,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $150M from 29 investors (100% of the $150M target) as of the latest filing. Robert is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

RT
Biotechnology

Rubius Therapeutics, Inc.

Cambridge, MA · Jun 22, 2017 → Mar 1, 2018 · 2 filings
  • Mar 1, 2018 · D · $101,200,005 sold of $101,200,005 · 27 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 22, 2017 · D · $115,000,060 sold of $120,000,064 · 16 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $115M from 27 investors (100% of the $101.2M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

Seer Biosciences, Inc.

Boston, MA · Jan 4, 2018
  • Jan 4, 2018 · D · $6,000,000 sold of $6,000,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $6M from 11 investors (100% of the $6M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Biotechnology

Combined Therapeutics, Inc.

Cambridge, MA · Dec 12, 2017
  • Dec 12, 2017 · D · $250,000 sold of $2,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $250K from 4 investors (13% of the $2M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology

MICELL TECHNOLOGIES INC

Durham, NC · Jul 29, 2009 → Sep 19, 2017 · 6 filings
  • Sep 19, 2017 · D/A · $61,775,000 sold of $70,000,000 · 51 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 21, 2017 · D/A · $41,775,000 sold of $50,000,000 · 51 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 4, 2017 · D/A · $31,775,000 sold of $35,000,000 · 51 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 18, 2016 · D · $25,775,000 sold of $30,000,000 · 51 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 3, 2009 · D · $300,055 sold of $300,055 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 29, 2009 · D · $5,000,000 sold of $5,300,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $61.8M from 51 investors (88% of the $70M target) as of the latest filing. Robert is listed as director on 6 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

VT
Other Health Care

Verseau Therapeutics, Inc.

Auburndale, MA · Mar 30, 2017
  • Mar 30, 2017 · D · $4,300,000 sold of $11,450,000 · 5 investors · min. No minimum reported · role: Director, Promoter EDGAR ↗

Raised $4.3M from 5 investors (38% of the $11.4M target) as of the latest filing. Robert is listed as director, promoter.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

XP
Pharmaceuticals

XTuit Pharmaceuticals, Inc.

Waltham, MA · Jan 31, 2014 → Sep 2, 2016 · 4 filings
  • Sep 2, 2016 · D/A · $22,016,999 sold of $22,016,999 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 11, 2015 · D/A · $12,008,500 sold of $22,017,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 5, 2014 · D · $4,000,000 sold of $10,000,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 31, 2014 · D · $1,508,513 sold of $1,508,513 · 2 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $22M from 10 investors (100% of the $22M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MT
Biotechnology · group: Moderna

Moderna Therapeutics, Inc.

Cambridge, MA · Aug 24, 2016
  • Aug 24, 2016 · D · $451,369,079 sold of $599,999,992 · 72 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $451.4M from 72 investors (75% of the $600M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

KB
Biotechnology

KALA BIO, Inc.

Arlington, MA · Dec 23, 2009 → Apr 13, 2016 · 7 filings
  • Apr 13, 2016 · D · $67,921,796 sold of $67,921,796 · 25 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 19, 2015 · D · $6,999,999 sold of $6,999,999 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 24, 2014 · D · $22,500,000 sold of $22,500,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Feb 28, 2013 · D · $5,750,059 sold of $11,500,118 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 14, 2012 · D · $7,243,205 sold of $7,243,205 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 10, 2010 · D · $3,000,000 sold of $3,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 23, 2009 · D · $2,000,001 sold of $2,000,001 · 10 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $67.9M from 26 investors (100% of the $67.9M target) as of the latest filing. Robert is listed as director on 7 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

CT
Biotechnology

Cartesian Therapeutics, Inc.

Gaithersburg, MD · Apr 6, 2010 → Sep 10, 2015 · 8 filings
  • Sep 10, 2015 · D · $37,400,000 sold of $40,637,943 · 19 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 23, 2015 · D · $5,942,306 sold of $7,500,000 · 12 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 28, 2014 · D · $4,450,000 sold of $4,450,000 · 11 investors · min. $100,000 · role: Director EDGAR ↗
  • Jul 15, 2014 · D · $6,000,000 sold of $6,000,000 · 2 investors · min. $3,000,000 · role: Director EDGAR ↗
  • Apr 9, 2014 · D · $5,292,702 sold of $9,999,994 · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 17, 2011 · D · $3,500,000 sold of $26,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 17, 2011 · D · $22,000,000 sold of $22,000,000 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 6, 2010 · D · $15,000,006 sold of $15,000,006 · 14 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $130M from 26 investors (100% of the $40.6M target) as of the latest filing. Robert is listed as director on 8 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

MB
Other Health Care

Microchips Biotech, Inc.

Lexington, MA · Mar 20, 2009 → Jun 24, 2015 · 2 filings
  • Jun 24, 2015 · D · $18,648,546 sold of $18,648,546 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Mar 20, 2009 · D · $9,212,500 sold of $23,250,000 · 11 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.6M from 11 investors (100% of the $18.6M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

M
Pharmaceuticals · group: Moderna

Moderna LLC

Cambridge, MA · Nov 20, 2013 → Jan 5, 2015 · 3 filings
  • Jan 5, 2015 · D · $446,069,409 sold of $502,168,634 · 43 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 23, 2014 · D/A · $135,000,044 sold of $135,000,044 · 40 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 20, 2013 · D · $110,000,026 sold of $110,000,026 · 39 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $446.1M from 43 investors (89% of the $502.2M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Pharmaceuticals / 506(b) (800 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

SB
Biotechnology

SQZ Biotechnologies Co

Watertown, MA · Apr 3, 2014
  • Apr 3, 2014 · D · $15,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $71.3M from 48 investors (100% of the $1M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(b) (3,253 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

E
Biotechnology

EGEN, Inc.

Huntsville, AL · Sep 19, 2012 → Oct 25, 2013 · 3 filings
  • Oct 25, 2013 · D · $3,917,335 sold of $3,917,335 · 5 investors · min. $250,000 · role: Director EDGAR ↗
  • Sep 21, 2012 · D · $7,499,997 sold of $7,499,997 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 19, 2012 · D · $7,015,293 sold of $7,015,293 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.5M from 7 investors (100% of the $3.92M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Biotechnology / 506(c) (163 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

TB
Biotechnology

TARIS BIOMEDICAL INC

Lexington, MA · Dec 16, 2009 → Apr 4, 2013 · 4 filings
  • Apr 4, 2013 · D/A · $18,372,751 sold of $18,717,021 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 2, 2013 · D/A · $13,500,000 sold of Indefinite · 11 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 13, 2011 · D · $18,372,751 sold of $18,717,021 · 8 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 16, 2009 · D · $5,000,001 sold of $5,000,001 · 7 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $18.4M from 11 investors (98% of the $18.7M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

TB
Other Technology

T2 Biosystems, Inc.

Lexington, MA · May 28, 2010 → Mar 28, 2013 · 3 filings
  • Mar 28, 2013 · D · $399,999,997 sold of $399,999,997 · 16 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 10, 2011 · D · $22,999,999 sold of $22,999,999 · 14 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 28, 2010 · D · $14,845,001 sold of $19,999,997 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $400M from 16 investors (100% of the $400M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

B
Biotechnology

Biorez, Inc.

New Haven, CT · Jul 20, 2009 → Mar 11, 2013 · 4 filings
  • Mar 11, 2013 · D/A · $4,210,000 sold of $4,250,000 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 29, 2011 · D · $1,250,000 sold of $2,500,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 7, 2010 · D/A · $2,804,767 sold of $3,054,767 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 20, 2009 · D · $1,054,767 sold of $2,554,767 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $7.67M from 36 investors (100% of the $4.25M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

LP
Other

LIVING PROOF INC

Cambridge, MA · Jun 18, 2009 → Feb 25, 2013 · 2 filings
  • Feb 25, 2013 · D · $30,000,000 sold of $35,000,000 · 9 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 18, 2009 · D · $9,000,000 sold of $9,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $30M from 9 investors (86% of the $35M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

BB
Biotechnology

BIND Biosciences, Inc

Cambridge, MA · Jun 29, 2010 → Feb 8, 2013 · 4 filings
  • Feb 8, 2013 · D · $8,697,684 sold of $20,250,000 · 20 investors · min. No minimum reported · role: Director EDGAR ↗
  • Nov 22, 2011 · D · $25,547,174 sold of $47,297,179 · 21 investors · min. No minimum reported · role: Director EDGAR ↗
  • Oct 13, 2011 · D · $4,750,000 sold of $4,750,000 · 5 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 29, 2010 · D · $12,420,952 sold of $12,420,952 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.5M from 21 investors (100% of the $20.3M target) as of the latest filing. Robert is listed as director on 4 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

CB
Biotechnology

Combinent BioMedical Systems, Inc.

Lexington, MA · Dec 16, 2009 → Oct 1, 2012 · 5 filings
  • Oct 1, 2012 · D · $600,000 sold of $600,000 · 2 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 4, 2012 · D · $750,000 sold of $750,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 29, 2010 · D · $1,021,267 sold of $3,008,987 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Sep 29, 2010 · D · $500,000 sold of $500,000 · 3 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 16, 2009 · D · $500,346 sold of $500,346 · 3 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $1.02M from 4 investors (100% of the $600K target) as of the latest filing. Robert is listed as director on 5 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

SB
Other Health Care

SEMPRUS BIOSCIENCES CORP

Cambridge, MA · Dec 22, 2010
  • Dec 22, 2010 · D · $9,004,031 sold of $18,804,034 · 5 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $9M from 5 investors (48% of the $18.8M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

DB
Pharmaceuticals

Dare Bioscience, Inc.

San Diego, CA · Jul 27, 2009 → Oct 13, 2010 · 3 filings
  • Oct 13, 2010 · D · $1,499,999 sold of $1,499,999 · 15 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jun 9, 2010 · D · $5,000,000 sold of $5,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jul 27, 2009 · D · $10,000,000 sold of $10,000,000 · 13 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $20.7M from 28 investors (100% of the $1.5M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

PB
Biotechnology

PREDICTIVE BIOSCIENCES, INC

Lexington, MA · Jan 19, 2010 → Jun 21, 2010 · 2 filings
  • Jun 21, 2010 · D · $25,368,777 sold of $25,368,777 · 10 investors · min. No minimum reported · role: Director EDGAR ↗
  • Jan 19, 2010 · D · $1,403,424 sold of $1,403,424 · 6 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $25.4M from 10 investors (100% of the $25.4M target) as of the latest filing. Robert is listed as director on 2 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

ET
Other Health Care

Echo Therapeutics, Inc.

Iselin, NJ · Jul 28, 2009 → Dec 7, 2009 · 3 filings
  • Dec 7, 2009 · D · $562,500 sold of $562,500 · 9 investors · min. $12,500 · role: Director EDGAR ↗
  • Nov 20, 2009 · D · $3,011,320 sold of $3,600,000 · 8 investors · min. $56,250 · role: Director EDGAR ↗
  • Jul 28, 2009 · D · $2,006,031 sold of $2,006,031 · 1 investors · min. $2,000,000 · role: Director EDGAR ↗

Raised $10M from 46 investors (100% of the $563K target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

AP
Biotechnology

ALSERES PHARMACEUTICALS INC /DE

Hopkinton, MA · Apr 1, 2009 → Nov 10, 2009 · 3 filings
  • Nov 10, 2009 · D · $1,000,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Aug 21, 2009 · D/A · $3,900,000 sold of $5,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗
  • Apr 1, 2009 · D · $1,000,000 sold of $1,000,000 · 1 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $3.9M from 1 investor (100% of the $1M target) as of the latest filing. Robert is listed as director on 3 filings for this deal.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

PT
Biotechnology

Pervasis Therapeutics Inc

Cambridge, MA · Sep 15, 2009
  • Sep 15, 2009 · D · $10,003,426 sold of $17,384,210 · 18 investors · min. No minimum reported · role: Director EDGAR ↗

Raised $10M from 18 investors (58% of the $17.4M target) as of the latest filing. Robert is listed as director.

Latest filing on EDGAR ↗
Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

Other pages with the same name (3)

Separate person records under the same name, not combined with this page. Each line says whether it shares an issuer with this record.

  • Robert Langer — PA, 2 issuers, Mar 29, 2010 → Aug 27, 2026 · no shared issuer
  • Robert Langer — CA, 1 issuer, Nov 16, 2010 → Mar 7, 2013 · no shared issuer
  • Robert S Langer — TX, 1 issuer, Apr 20, 2016 → Jun 19, 2019 · no shared issuer

People around Robert 40

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET. Showing the 40 with the most shared filings.

IC
Management entity

Invemed Catalyst Fund, L.P.

Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

GE
Management entity

General Electric Pension Trust

Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

KP
Management entity

Kendall Partners GP, LLC

Executive Officer, Promoter · 1 shared filing (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

PH
No photo found yet (own website and image search run after this page is viewed)
Person

Peter Barton Hutt

Director · 42 shared filings (9 issuers) · also on 6 other issuers

Peter Barton Hutt is on 15 issuers in total — a repeat sponsor. Their page lists every one.

AC
No photo found yet (own website and image search run after this page is viewed)
Person

Alan Crane

Director, Executive Officer · 28 shared filings (4 issuers) · also on 8 other issuers

Alan Crane is on 12 issuers in total — a repeat sponsor. Their page lists every one.

OF
No photo found yet (own website and image search run after this page is viewed)
Person

Omid Farokhzad

Director, Promoter · 21 shared filings (4 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

TM
No photo found yet (own website and image search run after this page is viewed)
Person

Terrance McGuire

Director · 17 shared filings (4 issuers) · also on 17 other issuers

Terrance McGuire is on 21 issuers in total — a repeat sponsor. Their page lists every one.

CT
No photo found yet (own website and image search run after this page is viewed)
Person

Carlo Giovanni Traverso

Director · 17 shared filings (4 issuers) · also on 2 other issuers

Carlo Giovanni Traverso is on 6 issuers in total — a repeat sponsor. Their page lists every one.

GW
No photo found yet (own website and image search run after this page is viewed)
Person

George Whitesides

Director · 16 shared filings (2 issuers) · also on 5 other issuers

George Whitesides is on 7 issuers in total — a repeat sponsor. Their page lists every one.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Aymeric Sallin

Director · 16 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

CR
No photo found yet (own website and image search run after this page is viewed)
Person

Carmichael Roberts

Director · 15 shared filings (2 issuers) · also on 26 other issuers

Carmichael Roberts is on 28 issuers in total — a repeat sponsor. Their page lists every one.

HW
No photo found yet (own website and image search run after this page is viewed)
Person

HOWARD WEISMAN

Executive Officer, Director · 15 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Langer. Their page shows their other deals.

AN
No photo found yet (own website and image search run after this page is viewed)
Person

Amir Nashat

Executive Officer, Director · 14 shared filings (4 issuers) · also on 25 other issuers

Amir Nashat is on 29 issuers in total — a repeat sponsor. Their page lists every one.

GN
No photo found yet (own website and image search run after this page is viewed)
Person

Guido Neels

Director · 14 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

HW
No photo found yet (own website and image search run after this page is viewed)
Person

HARRY WILCOX

Director, Executive Officer · 14 shared filings (2 issuers) · also on 5 other issuers

HARRY WILCOX is on 7 issuers in total — a repeat sponsor. Their page lists every one.

HB
No photo found yet (own website and image search run after this page is viewed)
Person

HOWARD BERNSTEIN

Executive Officer · 14 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Langer. Their page shows their other deals.

AS
No photo found yet (own website and image search run after this page is viewed)
Person

Amy Schulman

Executive Officer, Director · 12 shared filings (3 issuers) · also on 17 other issuers

Amy Schulman is on 20 issuers in total — a repeat sponsor. Their page lists every one.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

R. ROX ANDERSON

Director · 12 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Robert Langer. Their page shows their other deals.

EK
No photo found yet (own website and image search run after this page is viewed)
Person

Edwin M. Kania, Jr.

Director · 11 shared filings (3 issuers) · also on 3 other issuers

Edwin M. Kania, Jr. is on 6 issuers in total — a repeat sponsor. Their page lists every one.

MG
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Greeley

Director · 10 shared filings (4 issuers) · also on 14 other issuers

Michael Greeley is on 18 issuers in total — a repeat sponsor. Their page lists every one.

NA
No photo found yet (own website and image search run after this page is viewed)
Person

Noubar Afeyan

Director · 10 shared filings (4 issuers) · also on 10 other issuers

Noubar Afeyan is on 14 issuers in total — a repeat sponsor. Their page lists every one.

KB
No photo found yet (own website and image search run after this page is viewed)
Person

Kevin Bitterman

Director · 10 shared filings (2 issuers) · also on 22 other issuers

Kevin Bitterman is on 24 issuers in total — a repeat sponsor. Their page lists every one.

EC
No photo found yet (own website and image search run after this page is viewed)
Person

Earl M. Collier, Jr.

Director, Executive Officer · 9 shared filings (3 issuers) · also on 4 other issuers

Earl M. Collier, Jr. is on 7 issuers in total — a repeat sponsor. Their page lists every one.

RT
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Tepper

Director · 9 shared filings (2 issuers) · also on 13 other issuers

Robert Tepper is on 15 issuers in total — a repeat sponsor. Their page lists every one.

CR
No photo found yet (own website and image search run after this page is viewed)
Person

Catherine Reynolds

Director, Executive Officer · 9 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

CG
No photo found yet (own website and image search run after this page is viewed)
Person

Carl L. Gordon

Director · 8 shared filings (1 issuer) · also on 61 other issuers

Carl L. Gordon is on 62 issuers in total — a repeat sponsor. Their page lists every one.

MC
No photo found yet (own website and image search run after this page is viewed)
Person

Michael Cima

Executive Officer, Director · 8 shared filings (3 issuers) · also on 2 other issuers

Michael Cima is on 5 issuers in total — a repeat sponsor. Their page lists every one.

JG
No photo found yet (own website and image search run after this page is viewed)
Person

James Goldstein

Director · 8 shared filings (2 issuers) · also on 14 other issuers

James Goldstein is on 16 issuers in total — a repeat sponsor. Their page lists every one.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

James Barrett

Director · 8 shared filings (2 issuers) · also on 5 other issuers

James Barrett is on 7 issuers in total — a repeat sponsor. Their page lists every one.

GS
No photo found yet (own website and image search run after this page is viewed)
Person

George Siber

Director · 8 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Langer. Their page shows their other deals.

JR
No photo found yet (own website and image search run after this page is viewed)
Person

James Rosen

Director · 8 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

YU
No photo found yet (own website and image search run after this page is viewed)
Person

Yuriy Udaltsov

Director · 8 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

DD
No photo found yet (own website and image search run after this page is viewed)
Person

Dennis Dougherty

Director · 7 shared filings (2 issuers)

Listed on the same filings as Robert Langer. Their page shows their other deals.

DA
No photo found yet (own website and image search run after this page is viewed)
Person

Dennis Ausiello

Director · 7 shared filings (2 issuers) · also on 2 other issuers

Listed on the same filings as Robert Langer. Their page shows their other deals.

BD
No photo found yet (own website and image search run after this page is viewed)
Person

Brady W. Dougan

Director · 7 shared filings (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

LN
No photo found yet (own website and image search run after this page is viewed)
Person

Laura E. Niklason

Executive Officer, Director · 7 shared filings (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

MW
No photo found yet (own website and image search run after this page is viewed)
Person

Max Wallace

Director · 7 shared filings (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

RA
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Anderson

Director · 7 shared filings (1 issuer)

Listed on the same filings as Robert Langer. Their page shows their other deals.

RP
No photo found yet (own website and image search run after this page is viewed)
Person

Robert Paull

Executive Officer, Director, Promoter · 7 shared filings (1 issuer) · also on 6 other issuers

Robert Paull is on 7 issuers in total — a repeat sponsor. Their page lists every one.

WC
No photo found yet (own website and image search run after this page is viewed)
Person

Werner Cautreels

Executive Officer, Director · 7 shared filings (1 issuer) · also on 2 other issuers

Listed on the same filings as Robert Langer. Their page shows their other deals.

The team behind the deals

M
Sponsor group

Moderna

2 issuers · 4 filings · $897.4M reported sold · 2013–2016

One team, 2 deal companies. Robert Langer is listed on 2 of them.

Sources

Issuers are grouped when their Form D filings share related persons, a management entity or a business address (automatic match from the filings). "Listed" marks the issuers that name Robert Langer.

Same business address

51 other issuers file from the same address (first 50 shown)

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Adviser registration (Form ADV)

None of the 48 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Robert Langer by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 48 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Robert Langer is listed on: none on file. No website or social profile named in Moderna Therapeutics, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #284,209 of 374,652 in line (14 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Cambridge, MA). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Social and web

LinkedIn people search ↗Instagram ↗X (Twitter) ↗Facebook ↗YouTube ↗Google ↗Google Images ↗Google News ↗Meta Ad Library ↗

Courts

CourtListener / RECAP (federal) ↗PACER case locator (federal, login) ↗New York WebCivil Supreme ↗Massachusetts MassCourts ↗North Carolina eCourts portal ↗Connecticut Judicial Branch case look-up ↗Utah state courts — find the court ↗New Jersey state courts — find the court ↗California — find the county court ↗Los Angeles Superior Court case search ↗Maryland Judiciary case search ↗Alabama state courts — find the court ↗

Securities regulators

SEC EDGAR full-text search ↗SEC action look-up ↗FINRA BrokerCheck ↗SEC IAPD adviser search ↗

Business registries

New York Secretary of State business search ↗Massachusetts Secretary of State business search ↗North Carolina Secretary of State business search ↗Connecticut Secretary of State business search ↗Utah Secretary of State business search ↗New Jersey Secretary of State business search ↗California Secretary of State business search ↗Maryland Secretary of State business search ↗Alabama Secretary of State business search ↗OpenCorporates ↗

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Robert Langer appears on a new Form D, or when a court case or SEC action is matched to them. See plans →